Incyte | INCY - Equity Capital And Reserves


Incyte reported $6.34B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
BioCryst Pharmaceuticals USD -454.29M 99.55M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Exelixis USD 1.94B 225.57M Mar/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
Incyte USD 6.34B 721.58M Jun/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Merck USD 41.93B 3.94B Jun/2026
Moderna USD 6.76B 647M Jun/2026
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD -165.36M 15.1M Jun/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 1.53B 22.7M Jun/2026
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026